China has overtaken the United States in healthy life expectancy at birth for the first time, according to World Health Organization data.
Two Swiss freestyle skiers were the first athletes confirmed to have been hit by a highly contagious virus that causes vomiting and diarrhea at the Pyeongchang Winter Games, the Swiss Olympic team confirmed on Friday.
Pyeongchang Winter Olympics organizers (POCOG) said on Monday a total of 177 norovirus cases had been confirmed so far at the Games, but that the athletic delegations remained unaffected.
Olympic officials are discussing measures to combat the spread of a virus that causes vomiting and diarrhea after 42 new cases were confirmed at the Winter Games, a Korean Centers for Disease Control and Prevention (KCDC) official said.
The number of people struck down by a virus causing vomiting and diarrhea at the Pyeongchang Winter Olympics has more than doubled to 86, though athletes remain unaffected, the Korean Centers for Disease Control and Prevention (KCDC) said.
Teva Pharmaceutical Industries and South Korea’s Celltrion said the U.S. Food and Drug Administration has accepted for review a biologics application for a biosimilar drug to treat breast cancer.
South Korea’s antitrust regulator said it would fine Novartis’ local unit 500 million won ($444,089) for alleged unfair promotions, in another setback for the Swiss drugmaker that was fined earlier during 2017 over kickbacks to doctors.
Array BioPharma And Pierre Fabre Announce Development And Commercialization Collaboration For Two Novel Oncology Products, Binimetinib And Encorafenib
– Array to receive a $30 million up-front payment and up to $425 million in additional development and commercialization milestones, as well as robust double-digit royalties on future sales – – Array retains full commercialization rights to binimetinib and encorafenib in United States, Canada, Japan and Korea – -NEMO Phase 3 trial remains on-track for […]
Regeneron Announces Collaboration with Mitsubishi Tanabe Pharma for Investigational Pain Therapy Fasinumab in Asia
NGF Antibody Fasinumab Currently in Phase 2/3 Osteoarthritis Trial Tarrytown, N.Y., Oct. 1, 2015 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced a collaboration with Mitsubishi Tanabe Pharma Corporation (TSE: 4508) (MTPC) providing MTPC with exclusive development and commercial rights to fasinumab (REGN475), Regeneron’s NGF antibody in late-stage development for musculoskeletal pain. Under […]